Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: Correlations with proliferation markers, p53 expression and survival

Acta Neuropathologica

Volumn 95, Issue 6, 1998, Pages 617-624

  Korkolopoulou, Penelope ^a,b   Kouzelis, Konstantinos ^a   Christodoulou, Panayota ^a   Papanikolaou, Athanassios ^a   Thomas Tsagli, Euphemia ^a  

^a Asklepeion Voula Hospital   (Greece)

^b NONE   (Greece)

Author keywords

Cip 1; Glioma; p21 protein; Retinoblastoma gene; WAF1

Indexed keywords

CYCLINE; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DISRUPTION; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RETINOBLASTOMA; GLIOMA; HUMANS; KI-67 ANTIGEN; LIFE TABLES; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; OLIGODENDROGLIOMA; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031749730     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004010050848     Document Type: Article

References (42)

1. Brookstein R, Shew JY, Chen PL, Scully P, Lee WH (1990) Suppression of tumourigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 247:712-715
2. Chellapan SP, Hiebert S, Mudryj M, Horowitz JM, Nevin JR (1991) The E2F transcription factor is a cellular target for the Rb protein. Cell 65:1053-1061
3. Chen J, Jackson PK, Kirschner MW, Dutta (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386-388
4. Chozick BS, Pezzullo JC, Epstein MH, Finch PW (1994) Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35:831-838
5. Coons SW, Johnson PC (1993) Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 52:609-618
6. Cox DR (1972) Regression models and life tables. J Roy Stat B 34:187-220
7. Cunningham J, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB (1997) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86:121-130
8. Deimling A von, Eibl RH, Ohgaki H, Louis DN, Ammon K von, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR (1992) p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52:2987-2990
9. DiGiuseppe JA, Redstone MS, Yeo CJ, Kern SE, Hrulan RH (1995) p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 147: 884-888
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potent mediator of p53 tumor suppression. Cell 75: 817-825
11. Geradts J, Hu S-X, Lincoln CE, Benedict WF, Xu H-J (1994) Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int J Caner 58:161-167
12. Goodrich DW, Wang WP, Qian Y-W, Lee E Y-P, Lee WH (1991) The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67:293-302
13. Granna X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211-219
14. Harbour JW, Li S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ (1988) Abonormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-357
15. Harper JW, Adami GR, Wei N, Keyomarsi E, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816
16. He J, Olson JJ, James CD (1995) Lack of p16 (INK4) or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distrinct subsets of malignant glial cell tumors and cell lines. Cancer Res 55:4833-4836
17. Henson JW, Schnitker BL, Correa KM, Deimling A von, Fassbender F, Xu H-J, Benedict WF, Yandell DW, Louis DN (1994) The retinoblastoma susceptibility (Rb) gene is involved in the malignant progression of human astrocytomas. Ann Neurol 36: 714-721
18. Horowitz JM, Yandell DW, Park S-H, Canning S, Whyte P, Buchkovich KJ, Harlew E, Weinberg RA, Dryja TP (1989) Point mutational inactivation of the retinoblastoma antioncogene. Science 243:937-940
19. Horowitz JM, Park S-H, Bogenmann E, Cheng J-C, Yandell DM, Kaye FJ, Minna JD, Dryja TP, Weinberg RA (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775-2779
20. Jung J-M, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W (1995) Increased levels of p21 (WAF1/Cip1) in human brain tumors. Oncogene 11:2021-2028
21. Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3:255-268
22. Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, Deimling A von (1995) Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer 72:1230-1233
23. Lee EY-HP, To H, Shew J-Y, Brookstein R, Scully P, Lee W-H (1988) Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218-221
24. Lin BT-Y, Gruenwold S, Morla AO, Lee WH, Wang JY (1991) Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 10:857-864
25. Luo Y, Hurwitz J, Massagué J (1995) Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 Cip1. Nature 375:159-161
26. Mateo MS, Sanchez-Beato M, Martinez JC, Orfao A, Orradre JL, Piris MA (1995) p53, Rb and bcl2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microware irradiated lymphoid tissue sections. J Clin Pathol 48:151-159
27. Nakamura M, Konishi N, Hiasa Y, Tsunoda S, Fukushima Y, Tsuzuki T, Takemura K, Aoki H, Kobitsu K, Sakaki T (1996) Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. Int J Oncol 8:889-893
28. Norton AJ, Jordan S, Yeomans P (1994) Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173:371-379
29. Ono Y, Tamiya T, Ichikawa I, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN (1996) Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 55:1026-1031
30. Ono Y, Tamiya T, Ichikawa I, Matsumoto K, Furuta T, Ohmoto T, Akiyama K, Seki S, Ueki K, Louis DN (1997) Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol 94:21-27
31. Reissmann PT, Simon MA, Lee WH, Slamon DJ (1989) Studies of the retinoblastoma gene in human sarcomas. Oncogene 4:839-843
32. Sanchez-Beato M, Martinez-Montero JC, Doussis-Anagnostopoulou TA, Gatter KC, Garcia J, Garcia JF, LLoret E, Piris MA (1996) Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: a comparative study with p53 and Ki-67 expression. Br J Cancer 74:1056-1062
33. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takenchi S, Yang R, Chen D-L, Vogelstein B, Koeffler PH (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784
34. Soini Y, Niemela A, Kamel D, Herva R, Bloigu R, Paako P, Vahakangas K (1994) p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS 102:786-792
35. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M (1996) Alterations of retinoblastoma, p53, p16 (CDKN2) and p15 genes in human astrocytomas. Cancer 78:287-293
36. Ueki K, Ono Y, Henson JW, Efird JT, Deimling A von, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153
37. Venter DJ, Bevan KL, Ludwig RL, Riley TL, Jat PS, Thomas DG, Noble MD (1991) Retinoblastoma gene deletions in human glioblastomas. Oncogene 6:445-448
38. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kineases. Nature 366:701-704
39. Xu H-J, Xu S-X, Benedict WF (1991) Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene 6:1139-1144
40. Zhang H, Hannon GJ, Beach D (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8: 1750-1758
41. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travoli S, Deisseroth AB, Mercer WE (1995) p53 independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55:668-674
42. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB (1995) High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in clinical acute myelogenous leukemia. Cancer Res 1:1051-1057